03.03.09
Pfizer has entered into a series of agreements with Aurobindo Pharma Ltd., an India-based pharmaceutical company, to commercialize generics in the U.S. and Europe.
“We will dramatically change Pfizer’s Established Products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives,” said David Simmons, president and general manager of Pfizer’s Established Products Business Unit. Pfizer’s Established Products Business Unit was launched in 2008 as part of the company’s initiative to create smaller segments aligned with customer needs. This business unit has annual global sales of $10 billion.
Pfizer has acquired rights to 39 generic solid oral dose products in the U.S., 20 in Europe, and 11 in France. The drugs cover therapeutic areas including CV disease and CNS disorders, and will be commercialized in the U.S. through Pfizer’s Greenstone subsidiary. Pfizer has also acquired rights to 12 sterile injectable antibiotic products in the U.S. and Europe that include penicillins and cephalosporins.
Pfizer and Aurobindo's previous agreements from July 2008 include five products in the U.S. The two transactions total 44 solid oral dose products in the U.S.
“We will dramatically change Pfizer’s Established Products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives,” said David Simmons, president and general manager of Pfizer’s Established Products Business Unit. Pfizer’s Established Products Business Unit was launched in 2008 as part of the company’s initiative to create smaller segments aligned with customer needs. This business unit has annual global sales of $10 billion.
Pfizer has acquired rights to 39 generic solid oral dose products in the U.S., 20 in Europe, and 11 in France. The drugs cover therapeutic areas including CV disease and CNS disorders, and will be commercialized in the U.S. through Pfizer’s Greenstone subsidiary. Pfizer has also acquired rights to 12 sterile injectable antibiotic products in the U.S. and Europe that include penicillins and cephalosporins.
Pfizer and Aurobindo's previous agreements from July 2008 include five products in the U.S. The two transactions total 44 solid oral dose products in the U.S.